Melba Avila
Research Subjects
Melba Avila has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Adnolys Reyes
Neuroradiology; National Institute of Neurology and Neurosurgery; Havana, Cuba
1 shared publication- Ernesto Echevarria
Neurosurgery; Juan Manuel Márquez Pediatric Hospital; Havana, Cuba
1 shared publication Giselle Saurez
Center of Molecular Immunology; Havana, Cuba
1 shared publicationJorge L. Pedrayes
Oncohematology; Juan Manuel Márquez Pediatric Hospital; Havana, Cuba
1 shared publication- Jose Valdes
Oncohematology; Juan Manuel Márquez Pediatric Hospital; Havana, Cuba
1 shared publication José Alert
Radiotherapy; National Institute of Oncology and Radiobiology; Havana, Cuba
1 shared publication
Latest Publications
- 1 March 2013
- Published by Taylor & Francis in mAbs
- Vol. 5 (2) , 202-207
Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience
Brain tumors are a major cause of cancer-related mortality in children. Overexpression of epidermal growth factor receptor (EGFR) is detected in pediatric brain tumors and receptor density appears to increase with tumor grading. Nimotuzumab is an IgG1 antibody that targets EGFR. Twenty-three children with high-grade glioma (HGG) were enrolled in an expanded access program in which nimotuzumab was administered alone or with radio-chemotherapy. The mean number of doses was 39. Nimotuzumab was well-tolerated and treatment with the antibody yielded a survival benefit: median survival time was 32.66 mo and the 2-y survival rate was 54.2%. This study demonstrated the feasibility of prolonged administration of nimotuzumab and showed preliminary evidence of clinical benefit in HGG patients with poor prognosis.
- 1 March 2013
- Published by Taylor & Francis in mAbs
- Vol. 5 (2) , 202-207
Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience
Brain tumors are a major cause of cancer-related mortality in children. Overexpression of epidermal growth factor receptor (EGFR) is detected in pediatric brain tumors and receptor density appears to increase with tumor grading. Nimotuzumab is an IgG1 antibody that targets EGFR. Twenty-three children with high-grade glioma (HGG) were enrolled in an expanded access program in which nimotuzumab was administered alone or with radio-chemotherapy. The mean number of doses was 39. Nimotuzumab was well-tolerated and treatment with the antibody yielded a survival benefit: median survival time was 32.66 mo and the 2-y survival rate was 54.2%. This study demonstrated the feasibility of prolonged administration of nimotuzumab and showed preliminary evidence of clinical benefit in HGG patients with poor prognosis.